Technical Analysis for PRLD - Prelude Therapeutics Incorporated
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| BB Squeeze Ended | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| 50 DMA Resistance | Bearish | 1.24% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 1.24% | |
| 20 DMA Support | Bullish | 1.24% | |
| Bollinger Band Squeeze | Range Contraction | 1.24% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 1.24% |
| Alert | Time |
|---|---|
| Possible Inside Day | 4 days ago |
| 1.5x Volume Pace | 4 days ago |
| Gap Up Closed | 4 days ago |
| Gap Up Partially Closed | 4 days ago |
| Fell Below 10 DMA | 4 days ago |
Get a Trading Sidekick!
- Earnings date: 05/14/2024
Prelude Therapeutics Incorporated Description
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Lymphoma Blastoma Glioblastoma Protein Kinase Inhibitor Tyrosine Kinase Receptors Small Molecule Therapies Glioblastoma Multiforme Phosphoinositide 3 Kinase Inhibitor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.025 |
| 52 Week Low | 1.66 |
| Average Volume | 40,927 |
| 200-Day Moving Average | 3.60 |
| 50-Day Moving Average | 4.33 |
| 20-Day Moving Average | 3.93 |
| 10-Day Moving Average | 4.04 |
| Average True Range | 0.38 |
| RSI (14) | 50.74 |
| ADX | 14.38 |
| +DI | 14.33 |
| -DI | 13.73 |
| Chandelier Exit (Long, 3 ATRs) | 3.28 |
| Chandelier Exit (Short, 3 ATRs) | 4.70 |
| Upper Bollinger Bands | 4.27 |
| Lower Bollinger Band | 3.58 |
| Percent B (%b) | 0.74 |
| BandWidth | 17.79 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.08 |
| MACD Histogram | 0.047 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.65 | ||||
| Resistance 3 (R3) | 4.65 | 4.46 | 4.55 | ||
| Resistance 2 (R2) | 4.46 | 4.32 | 4.46 | 4.52 | |
| Resistance 1 (R1) | 4.28 | 4.23 | 4.19 | 4.28 | 4.49 |
| Pivot Point | 4.09 | 4.09 | 4.05 | 4.09 | 4.09 |
| Support 1 (S1) | 3.91 | 3.95 | 3.82 | 3.91 | 3.69 |
| Support 2 (S2) | 3.72 | 3.86 | 3.72 | 3.66 | |
| Support 3 (S3) | 3.54 | 3.72 | 3.63 | ||
| Support 4 (S4) | 3.54 |
